Encorafenib is a BRAF inhibitor increasingly used as a second-line treatment for metastatic melanoma and colorectal cancer. BRAF inhibitors have been reported to be associated with new and changing melanocytic lesions, including eruptive naevi. We describe two cases of eruptive naevi secondary to encorafenib used for the treatment of BRAF-mutant metastatic colorectal cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ced.15276 | DOI Listing |
Publication Analysis
Top Keywords
eruptive naevi
12
colorectal cancer
12
metastatic colorectal
8
naevi associated
4
associated encorafenib
4
encorafenib metastatic
4
cancer cases
4
cases encorafenib
4
encorafenib braf
4
braf inhibitor
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!